TL1A Inhibitor Deal Benchmarks in Gastroenterology

Median Upfront

$745M

Range: $398M - $1.1B

Total Deal Value

$3.8B

Range: $2.4B - $5.2B

Royalty Rate

8.5% - 15.8%

Tiered up to 19.8%

Dev Milestones

$641M

Range: $419M - $865M

Model Your Deal

Market Analysis

TL1A Inhibitor therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 tl1a inhibitor asset in gastroenterology is $745M, with total deal values reaching $3.8B. Development milestones average $641M, while regulatory milestones contribute $763M.

The gastroenterology tl1a inhibitor landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for tl1a inhibitor gastroenterology deals range from 8.5% to 15.8% at the base tier, with tiered escalation reaching 12.5%-19.8% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a tl1a inhibitor gastroenterology licensing deal?

Based on our analysis, Phase 2 tl1a inhibitor licensing deals in gastroenterology average $745M in upfront payments, with a range of $398M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for tl1a inhibitor gastroenterology transactions?

The median total deal value for Phase 2 tl1a inhibitor assets in gastroenterology is $3.8B, ranging from $2.4B to $5.2B. This includes development milestones ($641M), regulatory milestones ($763M), and commercial milestones ($1.6B).

What royalty rates are standard for tl1a inhibitor deals in gastroenterology?

Base royalty rates for tl1a inhibitor gastroenterology transactions range from 8.5% to 15.8%, with tiered escalations reaching 12.5%-19.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in tl1a inhibitor gastroenterology deals?

TL1A Inhibitor gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($641M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($763M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

TL1A Inhibitor Deal Benchmarks in Gastroenterology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Gastroenterology

Monoclonal Antibody in Gastroenterology

TL1A Inhibitor in Immunology & Autoimmune

Ready to Calculate Your Deal Terms?